Patent · US Active

CD95L or trail fusion proteins

US8147843B2 · kind B2 · utility

10Cited by

0References

24Claims

0Family size

Assignee

APOGENIX AG · DE

Inventors

Oliver Hill · Neckarsteinach, DE
Christian Gieffers · Dossenheim, DE
Meinolf Thiemann · Schriesheim, DE

Key dates

Filing date	Aug 28, 2007
Grant date	Apr 3, 2012
Priority date	—
Expiry date	May 24, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.